These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9013191)

  • 21. N2,N4,N6-tri(hydroxymethyl)-N2,N4,N6-trimethylmelamine (trimelamol) is an efficient DNA cross-linking agent in vitro.
    Jackson C; Hartley JA; Jenkins TC; Godfrey R; Saunders R; Thurston DE
    Biochem Pharmacol; 1991 Nov; 42(11):2091-7. PubMed ID: 1958227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methyl.
    Jarman M; Coley HM; Judson IR; Thornton TJ; Wilman DE; Abel G; Rutty CJ
    J Med Chem; 1993 Dec; 36(26):4195-200. PubMed ID: 8277501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized phase II trial of hexamethylmelamine versus pentamethylmelamine in carcinoma of the bilharzial bladder.
    Gad-el-Mawla N; Ziegler JL; Hamza R; Elserafi M; Khaled H
    Cancer Treat Rep; 1984 May; 68(5):793-4. PubMed ID: 6426792
    [No Abstract]   [Full Text] [Related]  

  • 24. Hexamethylmelamine. An evaluation of its role in the therapy of cancer.
    Legha SS; Slavik M; Carter SK
    Cancer; 1976 Jul; 38(1):27-35. PubMed ID: 820422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies of the mode of action of antitumour triazenes and triazines-V. The correlation of the in vitro cytotoxicity and in vivo antitumour activity of hexamethylmelamine analogues with their metabolism.
    Ross D; Langdon SP; Gescher A; Stevens MF
    Biochem Pharmacol; 1984 Apr; 33(7):1131-6. PubMed ID: 6424683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor effect of trimelamol against human breast carcinoma xenografts in nude mice.
    Yamada Y; Kubota T; Hoshiya Y; Asanuma F; Koh J; Kitajima M; Coley H; Judson I
    Oncol Rep; 1996 Jul; 3(4):613-7. PubMed ID: 21594422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I--II study of hexamethylmelamine plus dibromodulcitol in refractory carcinoma of the breast.
    Van Amburg AL; Presant CA; Vélez-García E; Klahr C
    Cancer Treat Rep; 1979 Jan; 63(1):141-2. PubMed ID: 105806
    [No Abstract]   [Full Text] [Related]  

  • 28. Phase II evaluation of hexamethylmelamine in advanced breast cancer: a Southwest Oncology Group study.
    Fabian CJ; Rasmussen S; Stephens R; Haut A; Smith F; Balcerzak S; Tranum B
    Cancer Treat Rep; 1979 Aug; 63(8):1359-61. PubMed ID: 113095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
    Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Studies on the stability of trimelamol, a carbinolamine-containing antitumor drug.
    Jackson C; Crabb TA; Gibson M; Godfrey R; Saunders R; Thurston DE
    J Pharm Sci; 1991 Mar; 80(3):245-51. PubMed ID: 2051341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapy of small cell carcinoma of the lung with hexamethylmelamine.
    Huang MN; Takita H; Catane H; Yee Chen T
    Oncology; 1978; 35(1):29-32. PubMed ID: 203884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy.
    Stehman FB; Ehrlich CE; Callangan MF
    Gynecol Oncol; 1984 Feb; 17(2):189-95. PubMed ID: 6423460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of a hexamethylmelamine and 5-fluorouracil combination in the treatment of advanced ovarian carcinoma.
    Kardinal CG; Luce JK
    Cancer Treat Rep; 1977 Dec; 61(9):1691-3. PubMed ID: 413624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regression of human lung tumor xenografts induced by water-soluble analogs of hexamethylmelamine.
    Connors TA; Cumber AJ; Ross WC; Clarke SA; Mitchley BC
    Cancer Treat Rep; 1977 Aug; 61(5):927-8. PubMed ID: 408005
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of phenobarbital pretreatment on the metabolism and antitumor activity of hexamethylmelamine.
    Paolini A; D'Incalci M
    Cancer Treat Rep; 1986 Apr; 70(4):513-6. PubMed ID: 3084083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phae II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy.
    Denefrio JM; Vogel CL
    Cancer Treat Rep; 1978 Jan; 62(1):173-5. PubMed ID: 414835
    [No Abstract]   [Full Text] [Related]  

  • 37. "Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?".
    Bruckner HW
    Cancer Treat Rep; 1987 Jun; 71(6):666-8. PubMed ID: 3107816
    [No Abstract]   [Full Text] [Related]  

  • 38. In vitro cytotoxicity of imidazolyl-1,3,5-triazine derivatives.
    Yaguchi S; Izumisawa Y; Sato M; Nakagane T; Koshimizu I; Sakita K; Kato M; Yoshioka K; Sakato M; Kawashima S
    Biol Pharm Bull; 1997 Jun; 20(6):698-700. PubMed ID: 9212994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies.
    Muindi JR; Newell DR; Smith IE; Harrap KR
    Br J Cancer; 1983 Jan; 47(1):27-33. PubMed ID: 6401427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.